HIF1A and cancer: This is well illustrated by the development history of PX-478, which demonstrated efficient target inhibition and a reasonable safety profile in a phase I dose-escalation study in cancer patients (NCT00522652); its clinical development has not advanced beyond early-phase trials, reflecting the broader difficulties in pharmacologically targeting HIF-1α [61].